Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login


The Cancer Letter Inc.
PO Box 9905
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Mar 31, 2016
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.


Two Phase III Anamorelin Trials Show Improved Lean Body Mass


Two phase III trials in non-small cell lung cancer patients with cachexia found that treatment with anamorelin significantly improved lean body mass and body weight compared to placebo, in addition to improving symptom burden, including appetite. No differences in handgrip strength were observed, one of the co-primary endpoints of the study.

Most participants in the trials were receiving chemotherapy. Improvements in patients’ weight and symptom burden were observed as early as three weeks and progressive, according to Helsinn, which sponsored the studies. The two studies, ROMANA 1 and ROMANA 2, were published in The Lancet Oncology.

To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.